1
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Neuroendocrine Tumors
2
Carcinoma, Neuroendocrine
1
Carcinoid Tumor
1
Interventions
Cisplatin
3202
Cyclophosphamide
3195
Carboplatin
2977
Radiotherapy
2790
Paclitaxel
2718
Gemcitabine
2572
pembrolizumab
2385
Bevacizumab
2209
Docetaxel
2199
Fluorouracil
1851
Capecitabine
1833
Oxaliplatin
1742
Dexamethasone
1605
Nivolumab
1581
Doxorubicin
1501
Rituximab
1488
Magnetic Resonance Spectroscopy
1387
Etoposide
1346
Irinotecan
1248
Leucovorin
1226
Drug Therapy
1205
Cytarabine
1130
Pemetrexed
1076
fludarabine
1063
Specimen Handling
1017
Vincristine
964
Cetuximab
945
Trastuzumab
945
Prednisone
942
Lenalidomide
937
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
177Lu-octreotate
×
Clear all
NCT02754297
2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2
Active not recruiting
275 enrolled
NCT01860742
2016-04-05
CASTOR
Jules Bordet Institute
Phase 3
Withdrawn